Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
- Funder
- National Institutes of Health
- Award amount
- Up to $150,000
- Deadline
- August 11, 2027
- Eligible countries
- United States
Summary
The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is sparse or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.
Summary as listed on Grants.gov (opportunity 357941). Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement on Grants.gov →What National Institutes of Health reviewers look for
- Importance of the research (significance and innovation), scored 1–9.
- Rigor and feasibility of the approach, scored 1–9. Preliminary data and alternative strategies carry much of this.
- Expertise and resources, rated sufficient or not, without a score.
- Overall impact: the likelihood the project will have a sustained, powerful influence on its field.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and GrantMatch scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free